Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib plus endocrine therapy in HR-positive, HER2-negative recurrent or metastatic breast cancer
2024-511497-79-00Phase 2Authorised
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of alisertib in breast cancer (2 arms), sponsored by Puma Biotechnology, Inc. Primary endpoints: Adverse events and serious adverse events, Objective response rate and 4 more. Planned start Dec 2024; status: authorised.
02
Drugs
alisertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-511497-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511497-79-00.